BioStock: BioInvent’s CEO comments on the study success in China

BioInvent’s partner in China, CASI Pharmaceuticals, has announced preliminary encouraging efficacy data for BioInvent’s lead drug candidate BI-1206 in combination with rituximab in cancer patients with non-Hodgkin’s lymphoma. BioStock reached out to BioInvent’s CEO Martin Welschof, who expects that 2024 will be a break-out year for the company, with multiple data readouts expected during the second half of the year.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2024/03/bioinvents-ceo-comments-on-the-study-success-in-china/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/